Role of radiation therapy in localized aggressive lymphoma

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 757-759

  Ng, Andrea K ^a   Mauch, Peter M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EDITORIAL; FOLLOW UP; HUMAN; LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; AGED; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NOTE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA; MIDDLE AGED; PREDNISONE; RANDOMIZED CONTROLLED TRIALS; VINCRISTINE;

EID: 33947541151     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.5562     Document Type: Editorial

References (14)

1. Bonnet C, Fillet G, Mounier N, et al: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients. J Clin Oncol 25:787-792, 2007
2. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
3. Miller T, Leblanc M, Spier C, et al: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98:724a, 2001
4. Reyes F, Lepage E, Ganem G, et al: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005 (abstr 3024)
5. Tilly H, Lepage E, Coiffier B, et al: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003
6. Fisher RI, Miller TP, O'Connor OA: Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221-236, 2004
7. Shenkier TN, Voss N, Fairey R, et al: Brief chemotherapy and involvedregion irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20:197-204, 2002
8. Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032-3038, 2004
9. Chao KS, Majhail N, Huang CJ, et al: Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. Radiother Oncol 61:275-280, 2001
10. Pow EH, Kwong DL, McMillan AS, et al: Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981-991, 2006
11. Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366:2087-2106, 2005
12. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
13. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
14. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006